Press Release

Mitsubishi Tanabe Pharma Corporation

January 29, 2015

- Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets -

Completion of New Manufacturing Facility

Tianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia

Osaka, Japan, January 29, 2015 - Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka; hereinafter, "the Company") announced today that the construction of new facilities have been completed at the plants of Tianjin Tanabe Seiyaku Co., Ltd. (Head Office: Tianjin, China) and P.T. Tanabe Indonesia (Head Office: Special Capital Region of Jakarta, Indonesia), overseas consolidated subsidiaries of the Company.

Under the Company's Medium-Term Management Plan 11-15, New Value Creation, establishing foundations for expanded overseas operations has been set as a major business strategy in promoting the Company's business activities. In Asia, including China, the Company strives not only to introduce products that have been approved in Japan, the US and Europe as rapidly as possible, but also to introduce products proactively in line with the needs and characteristics of each market. Because Chinese and Indonesian pharmaceutical markets are expected to grow further with increasing GDP, the Company has moved ahead with the construction of new buildings to increase production capacity to address this growing demand and to meet China's new GMP and Indonesia's PIC/S-GMP, newly-implemented GMP standards.

The Company has already started business activities in China, with Tianjin Tanabe Seiyaku Co., Ltd. dedicated to manufacture and sales of pharmaceuticals, Mitsubishi Pharma Research & Development (Beijing) Co., Ltd. (Head Office: Beijing) dedicated to development of pharmaceuticals, and Guangdong Tanabe Pharmaceutical Co., Ltd. (Head Office: Guangzhou) dedicated to sales of pharmaceuticals. With the start of operation at the new facilities that will boost production capacity to 300 million tablets per year, the Company's business operations are expected to expand still further.

-Continued
Since its establishment in 1970, P.T. Tanabe Indonesia has been manufacturing pharmaceutical products for supply to Indonesia and its neighboring countries. Commencement of operation at the new facility will boost the plant’s production capability by 1.75 times from the current level for a major product, Herbesser, an antihypertensive drug, and other solid preparations. The new facility will serve as a manufacturing base for Southeast Asia.

The Company will utilize these new facilities as a foundation for expanded operations in growing Asian markets and ensure a stable supply of high-quality pharmaceuticals. Furthermore, the Company will fulfill its responsibilities as a "global research-driven pharmaceutical company that is trusted by communities" by striving to contribute to the health of people around the world.

For the outline of each subsidiary and the new building, refer to the separate attachment.

<<For further information, contact>>
Corporate Communications Department
Phone: +81-6-6205-5211
Reference

Tianjin Tanabe Seiyaku
Corporate name: Tianjin Tanabe Seiyaku Co., Ltd.
Representatives: Chairman Zheng jie
                President Norihiko Okada
Foundation: October 1993
Paid-in capital: 16.23 million U.S. dollars
Equity holders: 75.35% by Mitsubishi Tanabe Pharma and 24.65% by Tianjin Lisheng Pharmaceutical Co., Ltd.
Business activities: Production and sales of pharmaceuticals
Annual sales: about ¥3.6 billion (for the year ended in December 2013)
Main products: Herbesser, Tanatril, Cerekinon, Gastrom, Talion
Production capacity: about 200 million tablets (as of the end of December 2014)
No. of employees: 521 (as of the end of December 2014)

Outline of new manufacturing facility
Location: No. 16 MIP Third Road, Micro-Electronics Industrial Park, Tianjin Economic-Technological Development Area, Tianjin, China
Start of construction: August 2013
Completion: January 2015
Scale of new facility: 2-story building (construction area: about 5,800 m², total floor space: about 7,200m²)
Total construction cost: about ¥1.9 billion (planned)
Designing and construction: Dalian Kaiser Construction Co., Ltd.

External appearance:
P.T. Tanabe Indonesia

Corporate name: P.T. Tanabe Indonesia
Representatives: President Kazuyuki Kashiba
Foundation: July 1970
Paid-in capital: 2.5 million U.S. dollars
Equity holders: 99.6% by Mitsubishi Tanabe Pharma
Business activities: Production and sales of pharmaceuticals
Annual sales: about ¥2.5 billion (for the year ended in March 2014)
Main products: Herbesser, Tanatril, Maintate, Livalo
Production capacity: about 100 million tablets (as of the end of December 2014)
No. of employees: 469 (as of the end of December 2014)

Outline of a production facility

Location: Jl. Rumah Sakit 104, Ujungberung, Bandung 40612, Indonesia
Start of construction: September 2013
Completion: January 2015
Scale of new facility: 3-story building (construction area: about 1,200 m²; total floor space: about 2,800m²)
Total construction cost: about ¥800 million
Designing and construction: P.T. SMCC UTAMA INDONESIA
(Sumitomo Mitsui Construction Co., Ltd.)

External appearance: